(120) Modeling the Effects of Global Opioid Treatment Recommendations on US Methadone and Buprenorphine Access

Background & Introduction: Medications for opioid use disorder (MOUD), including methadone and buprenorphine, cut all-cause mortality in half and improve retention and functioning. Yet globally, regulatory barriers limit access, contributing to avoidable deaths and escalating health costs. The United States exemplifies this gap: in 2023, less than 25% of people with opioid use disorder (OUD) received MOUD, compared to over 50% in France and the United Kingdom. This study compares national MOUD policies across eight countries (United States, Canada, United Kingdom, France, Portugal, Iran, Australia, and Russia) to examine how regulation and delivery models influence coverage and overdose mortality. It further estimates potential lives saved and net economic benefits if U.S. MOUD access were expanded. By integrating international evidence with a U.S.-based modeling analysis, this study identifies policy pathways that balance safety, feasibility, and public health impact. The central hypothesis is that aligning U.S. policy with higher-performing international models (e.g., through decentralization of methadone delivery and lower-risk buprenorphine scheduling) could yield substantial mortality and economic benefits, positioning regulatory reform as a critical lever in national overdose prevention.

Methods: We conducted a targeted review of peer-reviewed and policy literature describing MOUD frameworks in eight countries, representing diverse regulatory environments: prohibition (Russia), harm-reduction integration (Portugal, Iran), and liberalized primary-care models (France, U.K., Australia, Canada). Policies were categorized by prescriber eligibility, dispensing model (clinic-only vs. community pharmacy), take-home allowances, and buprenorphine scheduling. Opioid-related mortality rates were derived from the Global Burden of Disease 2021 dataset. For the modeling analysis, the U.S. was selected as a high-mortality, low-coverage reference case. National OUD prevalence was obtained from the 2023 National Survey on Drug Use and Health (5.7 million adults). Mortality reductions were derived from a meta-analysis (Sordo et al., 2017), indicating 9 deaths averted per 1,000 person-years of MOUD engagement. We modeled four coverage scenarios (25%, 50%, 75%, 100%) and calculated corresponding overdose deaths averted relative to the baseline 18% coverage. Economic benefits were estimated using CDC’s valuation of $11.55 million per life saved, adjusted for annual treatment costs ($6,552 per patient for methadone, $5,341 for buprenorphine) (Lou et al., 2017). Sensitivity analyses tested alternate mortality assumptions (5–12 per 1,000) and varying treatment adherence rates.

Results: Across eight countries, MOUD coverage and mortality closely mirrored regulatory flexibility. In the UK, buprenorphine carries the lowest risk classification (Class 3) and methadone is dispensed via community pharmacies, supporting >55% coverage and mortality < 4 per 100,000. France allows unrestricted buprenorphine prescribing and community methadone dispensing after initiation, achieving 87% coverage and 2.5 deaths per 100,000. Portugal and Iran combine decriminalization with low-threshold, pharmacy-based methadone access and liberal take-homes, maintaining ~60% coverage and mortality < 2 per 100,000. Australia and Canada classify both medications as high-risk (Schedule 8/I), but reaching ~50% coverage in most jurisdictions leveraging community pharmacy-based dispensing. In contrast, the US (methadone clinic confinement; buprenorphine Schedule III) and Russia (MOUD prohibited) exhibit the lowest coverage and highest mortality (16.7 per 100,000 in the US). Modeling based on national OUD prevalence and meta-analytic mortality reductions indicates that increasing U.S. MOUD coverage to 25%, 50%, 75%, and 100% could avert approximately 3,500, 13,500, 27,000, and 41,000 overdose deaths annually, respectively. Economic projections show $38–$444 billion in net savings even after treatment costs. Sensitivity analyses confirmed robustness across varying mortality and adherence assumptions, demonstrating that even partial coverage expansion yields substantial, measurable public health and economic gains.

Conclusion & Discussion: Global experience demonstrates that expanding MOUD access is achievable, safe, and cost-effective. France’s liberal buprenorphine model, the U.K.’s pharmacy-based dispensing, and Portugal and Iran's low-threshold integration illustrate scalable frameworks that normalize care while reducing stigma and overdose deaths. In contrast, restrictive systems that prohibit MOUD or confine its delivery to highly regulated, frequently inaccessible settings perpetuate geographic inequities, reinforce stigma, and sustain preventable mortality. Quantitative modeling suggests that US adoption of evidence-based reforms could save over 40,000 lives annually and generate hundreds of billions in net economic benefit. The findings support urgent alignment of US policy with international best practices, emphasizing three levers: (1) decentralization of methadone through community pharmacy dispensing, (2) rescheduling buprenorphine to reflect its safety profile, and (3) embedding MOUD into mainstream public health systems. Expanding access to these life-saving medications represents not only a moral and clinical imperative, but also a demonstrably cost-effective investment in population health, one capable of transforming the trajectory of the opioid crisis.

References: 1. Nunes JC, Costa GPA, De Aquino JP, et al. Expanding Access to Buprenorphine and Methadone: Global Perspectives and Policy Recommendations. Substance Use and Addiction Journal. 2025. In press.
2. Nunes JC, Adinoff B. Reducing Stigma and Expanding Access to Methadone in the U.S.: The Modernizing Opioid Treatment Access Act and Beyond. American Journal of Drug and Alcohol Abuse. 2025. Epub ahead of print. DOI: 10.1080/00952990.2025.2525405.
3. Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2021. Institute for Health Metrics and Evaluation (IHME). Accessed 08/28/2025, https://vizhub.healthdata.org/gbd-results/
4. Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. Bmj. 2017;357:j1550. Doi:10.1136/bmj.j1550
5. Substance Abuse and Mental Health Services Administration. 2023 National Survey on Drug Use and Health (NSDUH). Accessed 08/27/2025, https://www.samhsa.gov/data/release/2023-national-survey-drug-use-and-health-nsduh-releases
6. Luo F, Li M, Florence C. State-Level Economic Costs of Opioid Use Disorder and Fatal Opioid Overdose: United States, 2017. MMWR Morb Mortal Wkly Rep 2021; 70(15): 541–546.